Corrosion Resistance of Ti6Al4V Alloy by Radio Frequency Technique used for Coating Deposition of Multilayer (HA/TiN/Ti6Al4V-Substrate) for Optimization Power | Chapter 7 | Fundamental Research and Application of Physical Science Vol. 7

 The objective concerning this study is to perform material / chemical description and to determine the corrosion fighting of calcium-phosphate (HA), TiN-based biography-ceramics and thin metal enameling processed by a Ti-6Al-4V process. TiN and HA coating maximum capacity 150 watts. The presence of TiN200 Watt TiN s covering resulted in electrochemical corrosion. High current photoelectric and passive photoelectric polarization shows an active surface. EIS shows the alive behavior assumed apiece active photoelectric currents imposed. And HA on the sample surface, some cacophony was observed all along both polarization and EIS tests.

Author(s) Details:

Mustafa A. Mahmood,
Department of Medical Physic, College of Science, Alkarkh University of Science, Iraq.

M. A. Ulkareem,
Department of Physics, Baghdad Factuality Science, Baghdad, Iraq.

F. T. M. Noori,
Applied Physics Center, Materials Research Directorate, Iraq.

M. K. Khalaf,
Applied Physics Center, Materials Research Directorate, Iraq.

Please see the link here: https://stm.bookpi.org/FRAPS-V7/article/view/11123

A Novel Role of Candesartan and Ramipril in Attenuation of Liver Fibrosis in Patients with Chronic Hepatitis C Viral Infection | Chapter 7 | New Horizons in Medicine and Medical Research Vol. 11

 This research looked at how Candesartan and Ramipril affected individuals with chronic hepatitis C's liver fibrosis.

This randomised controlled prospective study included 64 participants with chronic hepatitis C and liver fibrosis. The participants were divided into three groups according to randomization: group I (control group; n=21), which got only conventional therapy; group 2 (Ramipril group; n=21); and group 3 (Candesartan group; n=22); which received just traditional therapy plus 8 mg/day oral Candesartan.

At the beginning, the demographic and laboratory data for the three research groups were statistically identical. In comparison to baseline data, the three research groups' post-treatment liver stiffness, HA and TGF-1 blood levels, and indicators of liver fibrosis all significantly decreased (p 0.001). When compared to the control group six months after therapy, patients taking Ramipril and Candesartan showed a substantial improvement in all analysed parameters. Additionally, the Candesartan group showed a significantly lower level of liver stiffness, biomarkers, and fibrosis indices when compared to the Ramipril group.

Patients with chronic hepatitis C who had liver fibrosis responded well to be successfully treated with ramipril and candesartan. A safe and effective therapy for liver fibrosis in people with chronic liver disease may be candesartan, an AT1-R antagonist that maintained anti-fibrotic action better than Ramipril.

Author(s) Details:

Tarek M. Mostafa,
Department of Clinical Pharmacy, Faculty of Pharmacy, Tanta University, Tanta, Egypt.

Gamal A. El-azab,
Department of Clinical Pharmacy, Faculty of Pharmacy, Tanta University, Tanta, Egypt.

Gamal A. Badra,
National Liver Institute, Faculty of Medicine, Menoufia University, Shebin El-kom, Egypt.

Alyaa S. Abdelwahed,
National Liver Institute, Faculty of Medicine, Menoufia University, Shebin El-kom, Egypt.

Abeer A. Elsayed,
Department of Clinical Pharmacy, Faculty of Pharmacy, Sinai University, Al-Arish, Egypt.

Please see the link here: https://stm.bookpi.org/NHMMR-V11/article/view/7142